Skip to main content
. Author manuscript; available in PMC: 2012 Jan 17.
Published in final edited form as: Vaccine. 2010 Nov 21;29(4):754–762. doi: 10.1016/j.vaccine.2010.11.015

Figure 1. IFN-γ ELISpot assay with pools of peptides that are predicted to bind avidly to HLA A02.

Figure 1

(A) Twenty-nine HLA-A*02-restricted peptides were divided in 5 pools with 8 to 9 peptides per pool and tested for reactivity in PBMCs isolated from HLA-matched T. gondii-seropositive individuals in an ex vivo ELISpot assay. A2P1 to A2P5: peptide pools as described in Table 1. IFN-γ ELISpot assay with individual peptides in pool 1 and pool 2 (B), pool 3 and pool 4 (C), pool 5 (D), These graphs show the spot count of each peptide that bound to HLA supertype HLA-A02 tested for reactivity with PBMCs isolated from HLA-A02 T. gondii-seropositive individuals. The peptides are listed by their sequence and antigen. * P<0.05; ** P<0.01; *** P<0.001.